Evidence map›Paper›PMID 36230978›Full record

ArticleCells2022

Delay of EGF-Stimulated EGFR Degradation in Myotonic Dystrophy Type 1 (DM1).

Eva Alegre-Cortés, Alberto Giménez-Bejarano, Elisabet Uribe-Carretero, Marta Paredes-Barquero, André R A Marques, Mafalda Lopes-da-Silva, Otília V Vieira, Saray Canales-Cortés, Pedro J Camello, Guadalupe Martínez-Chacón and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Mitochondrial Dysfunction in Repeat Expansion Diseases.Antioxidants (Basel, Switzerland) · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Eva Alegre-CortésDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.ORCID 0000-0002-0733-229X
Alberto Giménez-BejaranoDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.
Elisabet Uribe-CarreteroDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.ORCID 0000-0001-6477-5268
Marta Paredes-BarqueroDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.ORCID 0000-0002-5698-8180
André R A MarquesiNOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.ORCID 0000-0001-9674-3017
Mafalda Lopes-da-SilvaiNOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.
Otília V VieiraiNOVA4Health, NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal.ORCID 0000-0003-4924-1780
Saray Canales-CortésDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.
Pedro J CamelloDepartamento de Fisiología, Facultad de Veterinaria, Universidad de Extremadura, 10003 Cáceres, Spain.ORCID 0000-0001-5026-7166
Guadalupe Martínez-ChacónDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.
Ana AiastuiCentro de Investigación Biomédica en Red de Enfermedades (CIBERNED), 28031 Madrid, Spain.
Roberto Fernández-TorrónCentro de Investigación Biomédica en Red de Enfermedades (CIBERNED), 28031 Madrid, Spain.
Adolfo López de MunainCentro de Investigación Biomédica en Red de Enfermedades (CIBERNED), 28031 Madrid, Spain.ORCID 0000-0002-9509-4032
Patricia Gomez-SuagaDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.
Mireia Niso-SantanoDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.
Rosa A González-PoloDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.
José M FuentesDepartamento de Bioquímica y Biología Molecular y Genética, Facultad de Enfermería y Terapia Ocupacional, Universidad de Extremadura, Avda de la universidad s/n, 10003 Cáceres, Spain.ORCID 0000-0001-6910-2089
Sokhna M S Yakhine-DiopInstituto de Investigación Biosanitaria de Extremadura (INUBE), 06071 Cáceres, Spain.
Biomedical Research Networking Center on Neurodegenerative Diseases · ESInstituto de Investigación Biosanitaria de Granada · ESUniversidade Nova de Lisboa · PTUniversity of the Basque Country · ESUniversidad de Extremadura · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myotonic dystrophy type 1 (DM1) is an autosomal dominant disease caused by a CTG repeat expansion in the 3' untranslated region of the dystrophia myotonica protein kinase gene. AKT dephosphorylation and autophagy are associated with DM1. Autophagy has been widely studied in DM1, although the endocytic pathway has not. AKT has a critical role in endocytosis, and its phosphorylation is mediated by the activation of tyrosine kinase receptors, such as epidermal growth factor receptor (EGFR). EGF-activated EGFR triggers the internalization and degradation of ligand-receptor complexes that serve as a PI3K/AKT signaling platform. Here, we used primary fibroblasts from healthy subjects and DM1 patients. DM1-derived fibroblasts showed increased autophagy flux, with enlarged endosomes and lysosomes. Thereafter, cells were stimulated with a high concentration of EGF to promote EGFR internalization and degradation. Interestingly, EGF binding to EGFR was reduced in DM1 cells and EGFR internalization was also slowed during the early steps of endocytosis. However, EGF-activated EGFR enhanced AKT and ERK1/2 phosphorylation levels in the DM1-derived fibroblasts. Therefore, there was a delay in EGF-stimulated EGFR endocytosis in DM1 cells; this alteration might be due to the decrease in the binding of EGF to EGFR, and not to a decrease in AKT phosphorylation.

Indexed as

Epidermal Growth FactorMyotonic Dystrophy3' Untranslated RegionsErbB ReceptorsHumansLigandsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt3' Untranslated RegionsEGFR protein, humanEpidermal Growth FactorErbB ReceptorsLigandsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAKTautophagyDMPKendosomesLBPAlysosomesmuscle atrophy

Identifiers

PMID36230978
PMCPMC9562898
OpenAlexW4297348339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.